Summary

for people ages 60-85 (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).

Official Title

Assessment of Safety, Tolerability, and Efficacy of LY3303560 in Early Symptomatic Alzheimer's Disease

Keywords

Alzheimer Disease (AD)Memory problemsCognitive impairmentPERISCOPE-ALZDementiaTauopathyNeurofibrillary tanglesAlzheimer DiseaseLY3303560LY3303560 Dose 1LY3303560 Dose 2

Eligibility

You can join if…

Open to people ages 60-85

  • Participants must have gradual and progressive change in memory function for >6 months.
  • Participants must have a family member or close friend who is with you at least 10 hours per week and can attend study appointments.

You CAN'T join if...

  • Participants must not have significant neurological disease affecting the nervous system, other than AD, that affects cognition or may affect completion of the study.
  • Participants must not have serious or unstable illness that could interfere with the analysis of the study or has a life expectancy <24 months.
  • Participants must not have history of cancer within the last 5 years with the exception of certain types of skin, cervical, prostate, and other cancers that are not likely to recur or spread.
  • Participants must not have serious risk for suicide.
  • Participants must not have history of drug or alcohol use disorder within the last 2 years.
  • Participants must not have multiple severe drug allergies
  • Participants must not have HIV, Hepatitis B or Hepatitis C
  • Participants must not be receiving gamma globulin (IgG) or intravenous immunoglobulin (IVIG) therapy

Locations

  • Univ of California San Franciscoaccepting new patients
    San FranciscoCalifornia94158United States
  • National Research Instituteaccepting new patients
    Panorama CityCalifornia91402United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
ID
NCT03518073
Phase
Phase 2
Study Type
Interventional
Last Updated